Tag: pharmaceuticals
-
![Medexus Pharmaceuticals (MDP.TO) Q2 2023 revenue expected to exceed US$27 million]()
Medexus Pharmaceuticals (MDP.TO) Q2 2023 revenue expected to exceed US$27 million
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company that has been making big moves on the charts. The company is not a biotech company. They do not do research and development, but instead bring over drugs that are already licensed in Western Europe to North America which sees them carve out a nice and profitable…
-
![Today’s Idea: Valeo Pharma (VPH.C) Boasts an Impressive Portfolio and Achieves Significant Growth]()
Today’s Idea: Valeo Pharma (VPH.C) Boasts an Impressive Portfolio and Achieves Significant Growth
Even during my university days, I would find myself grasping my chest, wheezing after a short 15-minute walk to campus. In terms of fitness, I would consider myself to be above average. With this in mind, I found it startling that I was struggling to do something as trivial as walking to class. Drenched in…
-
![BetterLife Pharma (BETR.C) products show promise, but how’s their timing?]()
BetterLife Pharma (BETR.C) products show promise, but how’s their timing?
Drug science is all about timing. You can either take a preexisting molecule, which has benefits for alternative indications rather than what it’s originally on shelves for, and you after proving that it has these benefits during the regulatory dance, you take it to a new market, rebrand it and resell it. Easy. Or you…
-
![Undervalued Valeo Pharma (VPH.C) and their asthma inhalers may be 2021’s shiniest hidden gem]()
Undervalued Valeo Pharma (VPH.C) and their asthma inhalers may be 2021’s shiniest hidden gem
There’s nothing more terrifying than watching a loved one pause, clutch their throat and start gasping for air. The first time it happens provokes the mad scramble, as she points at her purse and mimes the universal L-shaped hand pattern for an asthma inhaler. She sits while you go digging through spent candy wrappers, old…
-
Cybin (CYBN.NEO): Grown up approach to psychedelics brings half billion valuation… so far
Back in January of this year, we told you about a psychedelics company that was going to come at that sector like many had talked about, but few had achieved. Their angle? Be a biotech company. Don’t dick about with fakey business plans or black velvet paintings of Elvis. No Jamaican B&Bs dressed up as…
-
![Medexus Pharmaceuticals (MDP.T) gets the Health Canada official nod to commercialize treosulfan]()
Medexus Pharmaceuticals (MDP.T) gets the Health Canada official nod to commercialize treosulfan
Medexus Pharmaceuticals (MDP.T) received Health Canada’s Notice of Compliance to commercialize treosulfan today, according to a press release. Treosulfan will be sold in Canada using the brand name Trecondyv®. It’s used in combination with another drug called fludarabine as part of a conditioning treatment prior to allogeneic hemapoietic stem cell transplantation. The treatment clears the…
-
![Cybin (CYBN.E) new tryptamine patent improves outcome quality]()
Cybin (CYBN.E) new tryptamine patent improves outcome quality
Cybin (CYBN.E) filed a new provisional patent application for its ongoing drug candidate programs today, according to a press release. The application includes compositions which the company anticipates will improve pharmacokinetic profiles while keeping efficacy measures of the original molecules. The company’s patent also offers new delivery systems to increase onset of Cybin’s psychedelic tryptamine,…
-
Revive Therapeutics (RVV.C) files for FDA Orphan Drug Designation for psilocybin in traumatic brain injury
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function after TBI lessening disability”.
-
![As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat]()
As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat
News this week that Canntab Therapeutics (PILL.C) received an Australian patent for their hard-pressed cannabis pill tech, to match those received earlier in North America, didn’t launch the stock into space. That’s understandable, to be honest, as North American investors have taken an eye off the island continent and its slow roll to weed legalization…
-
Sixth Wave (SIXW.C) surges 15% as Polymer Imprint detects SARS-CoV-2 during initial testing
“Molecularly imprinted polymers (MIPs) are synthetic polymers with a predetermined selectivity for a given analyte, or group of structurally related compounds, making them ideal materials to be used in separation processes,” explains Science Direct.
